Hellenic J Cardiol 2021 Jul 23. Epub 2021 Jul 23.
Minneapolis Heart Institute Foundation, Minneapolis, MN; Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN. Electronic address:
J Invasive Cardiol 2021 Sep 19;33(9):E717-E722. Epub 2021 Aug 19.
Background: The outcomes of distal radial access (dRA) in chronic total occlusion percutaneous coronary intervention (CTO-PCI) have received limited study.Methods: We compared the clinical, angiographic, and procedural characteristics of 120 CTO-PCIs performed via dRA access with 2625 CTO-PCIs performed via proximal radial access (pRA) in a large, multicenter registry.Results: The dRA group had lower mean PROGRESS-CTO score than the pRA group (1. Read More
Hellenic J Cardiol 2021 Jun 5. Epub 2021 Jun 5.
Minneapolis Heart Institute Foundation, Minneapolis, MN, USA; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA. Electronic address:
PLoS One 2021 2;16(4):e0245898. Epub 2021 Apr 2.
Servicio de Cardiología, H. Clínico de Valencia. Universidad de Valencia, CIBERCV, Valencia, Spain.
Background: We aimed to compare the performance of the recent CASTLE score to J-CTO, CL and PROGRESS CTO scores in a comprehensive database of percutaneous coronary intervention of chronic total occlusion procedures.Methods: Scores were calculated using raw data from 1,342 chronic total occlusion procedures included in REBECO Registry that includes learning and expert operators. Calibration, discrimination and reclassification were evaluated and compared. Read More
J Invasive Cardiol 2021 02;33(2):E135
Minneapolis Heart Institute, 920 East 28th Street #300, Minneapolis, MN 55407 USA.
We read with interest the study by Shaikh et al reporting that none of the patients with coronary chronic total occlusions (CTOs) and a prior Q-wave myocardial infarction (MI) in the CTO-supplied territory had viable myocardium even in the presence of good collateral circulation. Based on our large, multicenter registry on CTO in percutaneous coronary intervention, PROGRESS-CTO, we believe viability testing may still be of value in patients with a CTO and a prior MI, especially if their ejection fraction is low and dyspnea is the predominant symptom. Read More